ACADIA PHARMACEUTICALS INC. Current Liabilities
ACADIA PHARMACEUTICALS INC. (ACAD) had Current Liabilities of $361.44 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $361.44M.
- 2026-03-31: Liabilities, Current $305.52M.
- 2025-12-31: Liabilities, Current $277.11M.
- 2025-09-30: Liabilities, Current $356.58M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $361.44M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $305.52M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $277.11M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $356.58M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $330.02M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $302.53M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $394.87M 10-K · filed 2026-02-26 |
| 2024-09-30 | $343.94M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $337.85M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $330.60M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $254.25M 10-K · filed 2025-02-27 |
| 2023-09-30 | $209.60M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $187.94M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $224.30M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $125.63M 10-K · filed 2024-02-28 |
| 2022-09-30 | $116.57M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $117.68M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $119.60M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $96.07M 10-K · filed 2023-02-28 |
| 2021-09-30 | $88.22M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $95.33M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $109.37M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $105.97M 10-K · filed 2022-03-01 |
| 2020-09-30 | $91.86M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $86.42M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $99.74M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $74.83M 10-K · filed 2021-02-25 |
| 2019-09-30 | $67.74M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $63.81M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $74.98M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $59.56M 10-K · filed 2020-02-27 |
| 2018-09-30 | $41.81M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $49.21M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $46.09M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $49.03M 10-K · filed 2019-02-27 |
| 2017-09-30 | $36.14M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $40.91M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $45.27M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $42.59M 10-K · filed 2018-02-27 |
| 2016-09-30 | $39.15M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $29.02M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $21.12M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $21.90M 10-K · filed 2017-02-28 |
| 2015-09-30 | $17.73M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $19.38M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $16.65M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $15.83M 10-K · filed 2016-02-29 |
| 2014-09-30 | $11.25M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $9.34M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $8.03M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $6.98M 10-K · filed 2015-02-26 |
| 2013-09-30 | $7.87M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $7.78M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $5.70M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $5.95M 10-K · filed 2014-02-27 |
| 2012-09-30 | $6.09M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $6.76M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $6.43M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $6.17M 10-K · filed 2013-03-12 |
| 2011-09-30 | $6.41M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $5.95M 10-Q · filed 2011-08-10 |
| 2010-12-31 | $5.96M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |